Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

BackgroundThe Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to CD4+

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2017, Vol.4 (4), p.ofx262-ofx262
Hauptverfasser: Baker, Jason V, Sharma, Shweta, Grund, Birgit, Rupert, Adam, Metcalf, Julia A, Schechter, Mauro, Munderi, Paula, Aho, Inka, Emery, Sean, Babiker, Abdel, Phillips, Andrew, Lundgren, Jens D, Neaton, James D, Lane, H Clifford
Format: Artikel
Sprache:eng
Schlagworte:
Major
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundThe Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to CD4+
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofx262